The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Abstract
The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Self-citationExtended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Self-citationNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Cited by
Items 201–214 of 214
Page, M. G. P. (2012) · Antibiotic Discovery and Development · doi:10.1007/978-1-4614-1400-1_3 · Cited by 84
Enterocins: Classification, Synthesis, Antibacterial Mechanisms and Food Applications
Wu, Y., Pang, X., Wu, Y., Liu, X., & Zhang, X. (2022) · Molecules · doi:10.3390/molecules27072258 · Cited by 82
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
“the shortage of efficacious antibiotics against multidrug-resistant gram-negative bacteria) may result in unacceptably high mortality, hampering advances in chemotherapy.(336)”
BackgroundMcKinnell, J. A., Singh, R. D., Miller, L. G., Kleinman, K., Gussin, G., He, J., Saavedra, R., Dutciuc, T. D., Estevez, M., Chang, J., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz119 · Cited by 76
Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069646 · Cited by 73
“presently in development are effective against them [4,5].”
BackgroundMethodChin, D., Goncheva, M. I., Flannagan, R. S., Deecker, S. R., Guariglia-Oropeza, V., Ensminger, A. W., & Heinrichs, D. E. (2021) · Nature Communications · doi:10.1038/s41467-021-22175-3 · Cited by 72
Cyanobacteria and microalgae: A renewable source of bioactive compounds and other chemicals
Encarnação, T., Pais, A. A. C. C., Campos, M. G., & Burrows, H. D. (2015) · Science Progress · doi:10.3184/003685015x14298590596266 · Cited by 65
Gene Expression-Based Classifiers Identify Staphylococcus aureus Infection in Mice and Humans
Ahn, S. H., Tsalik, E. L., Cyr, D. D., Zhang, Y., van Velkinburgh, J. C., Langley, R. J., Glickman, S. W., Cairns, C. B., Zaas, A. K., Rivers, E. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0048979 · Cited by 61
van Limburg, M., Wentzel, J., Sanderman, R., & van Gemert-Pijnen, L. (2015) · JMIR Research Protocols · doi:10.2196/resprot.4519 · Cited by 59
Uppuluri, P., Lin, L., Alqarihi, A., Luo, G., Youssef, E. G., Alkhazraji, S., Yount, N. Y., Ibrahim, B. A., Bolaris, M. A., Edwards, J. E., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007056 · Cited by 57
Self-citationSiderophore-mediated iron acquisition by Klebsiella pneumoniae
Kumar, A., Chakravorty, S., Yang, T., Russo, T. A., Newton, S. M., & Klebba, P. E. (2024) · Journal of Bacteriology · doi:10.1128/jb.00024-24 · Cited by 42
Nitric Oxide Therapy for Dermatologic Disease
Adler, B. L., & Friedman, A. J. (2015) · Future Science OA · doi:10.4155/fso.15.37 · Cited by 43
Saifi, S., Ashraf, A., Hasan, G. M., Shamsi, A., & Hassan, M. I. (2024) · Fitoterapia · doi:10.1016/j.fitote.2023.105811 · Cited by 25
The Lactobacillus acidophilus Supernatant: An Effective and Safe Alternative to Antibiotics
Soleymanzadeh Moghadam, S., Minaeian, S., Majidpour, A., Adabi, M., & Hosseini Doust, R. (2024) · Iranian Journal of Toxicology · doi:10.61186/ijt.18.1.52 · Cited by 2
Metadata
- Authors
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 48
- Issue
- 1
- Pages
- 1-12
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2115486016
- Cited by
- 4,958
- References
- 66
- FWCI
- 162.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.